Esophageal Cancer Clinical Trials 2024

What are the top hospitals conducting esophageal cancer research?

When it comes to advancing the treatment options for esophageal cancer, several top hospitals are leading the way. In Houston, M D Anderson Cancer Center is at the forefront with an impressive 13 ongoing clinical trials focused on this challenging condition. Having initiated their first recorded trial in 2003, they have since conducted a total of 24 esophageal cancer trials, showcasing their commitment to finding better solutions for patients. Meanwhile, in Saint Louis, Washington University School of Medicine has been making significant contributions as well. With seven active esophageal cancer trials and a history of 18 completed studies dating back to their inaugural trial in 2005.

In Tampa's Moffitt Cancer Center also joins these pioneering institutions with six ongoing esophageal cancer clinical trials. Although having conducted only seven previous investigations since recording its first trial back in 2002; Moffitt's dedication is evident through their research efforts towards improving outcomes for patients battling this disease.

Further adding itself to this list is New york City's renowned Memorial Sloan Kettering Cancer Center where they currently have five active clinical trials dedicated solely to esophageal cancer after successfully completing twenty-three such investigations following their initiation into conducting them from fifteen years ago during its first recorded study held on same grounds starting from year2002

Finally the West coast enters with University of California Davis Comprehensive Cancer center joining the league by presenting five current tests being carried out pertaining exclusively towards Esophagal cases alongside completion of prior eight other related investigative projects; marked as relatively new player considering that theirs began approximately ten years ago since welcoming Esophagal subject matters within hospital compound.

These hospitals represent beacons of hope and progress in the field of esophageal cancer research. By actively pursuing innovative approaches and conducting rigorous clinical trials specific to this disease, they inspire confidence and provide opportunities for improved outcomes and quality of life for individuals affected by Esophagal malignancies

Which are the best cities for esophageal cancer clinical trials?

When it comes to esophageal cancer clinical trials, several cities stand out as leaders in research and development. New york City leads the way with 27 active trials investigating treatments like BMS-986340, Lenvatinib & Pembrolizumab, and other innovative approaches. Following closely behind is Houston, Texas, with 25 ongoing studies focusing on various treatment options such as Proton Beam Radiation Therapy and Nivolumab. Los Angeles, California also emerges as a prominent city for esophageal cancer clinical trials, with 23 active studies exploring treatments like DKN-01 and Pembrolizumab. These cities offer individuals battling esophageal cancer access to cutting-edge trials that hold promise for improved outcomes and new therapeutic options.

Which are the top treatments for esophageal cancer being explored in clinical trials?

The field of esophageal cancer research is abuzz with several promising treatments currently being explored in clinical trials. Among the top contenders are:

• Pharmacological Study, which has shown potential through three active trials and five all-time esophageal cancer trials since its first listing in 2010.
• Nivolumab, a breakthrough immunotherapy drug that is making waves with three ongoing trials and an impressive track record of 22 all-time esophageal cancer trials since its introduction in 2015.
• Pembrolizumab, another immunotherapy treatment that is showing promise in the fight against esophageal cancer, with three active trials and 31 all-time clinical studies conducted since it was listed as a treatment option back in 2014.
• Itraconazole, a newer player on the scene but already gaining attention for its potential benefits. It too boasts three active clinical trials dedicated to exploring its efficacy for treating esophageal cancer since it was first listed as a therapeutic option in 2016.

These exciting advancements offer hope for improved outcomes and better quality of life for individuals battling this challenging disease.

What are the most recent clinical trials for esophageal cancer?

Recent clinical trials have brought forth promising advancements in the field of esophageal cancer treatment. CA-4948, a Phase 1 trial initiated on June 2, 2023, has shown potential for esophageal cancer patients. Additionally, Enterotracker and Nutritional Supplementation are being explored through Phase 1 and Phase 3 trials respectively to determine their efficacy in managing this disease. Furthermore, the combination chemotherapy regime FOLFIRI (sFOLFOXIRI) is being investigated in a Phase 2 study that began on July 13, 2022. Another notable trial is examining the use of Neratinib plus TDxD for esophageal cancer treatment as part of a Phase 1 trial which commenced on June 24, 2022. These studies hold promise for improving outcomes and providing new therapeutic options for individuals affected by esophageal cancer.

What esophageal cancer clinical trials were recently completed?

Recently, several clinical trials investigating potential treatments for esophageal cancer have concluded, offering hope to patients and advancing our understanding of this challenging disease. In January 2021, EMD Serono Research & Development Institute completed a trial focusing on M1231. Furthermore, trials sponsored by City of Hope Medical Center (April 2019), Sidney Kimmel Cancer Center at Thomas Jefferson University (September 2018), M.D. Anderson Cancer Center (February 2018), Duke University (January 2018), Merck Sharp & Dohme LLC (July 2017), and Dana-Farber Cancer Institute (January 2017) have also reached completion in recent years. These accomplishments reflect the ongoing commitment of researchers to explore innovative therapeutic avenues for esophageal cancer treatment.